Compare PH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PH | SNY |
|---|---|---|
| Founded | 1917 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.2B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | PH | SNY |
|---|---|---|
| Price | $978.38 | $47.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 6 |
| Target Price | ★ $969.75 | $61.50 |
| AVG Volume (30 Days) | 737.2K | ★ 3.9M |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | 0.74% | ★ 3.34% |
| EPS Growth | 13.27 | ★ 44.16 |
| EPS | ★ 27.43 | 7.52 |
| Revenue | $20,461,000,000.00 | ★ $54,850,299,422.00 |
| Revenue This Year | $9.52 | $2.70 |
| Revenue Next Year | $7.26 | $6.84 |
| P/E Ratio | $35.60 | ★ $12.51 |
| Revenue Growth | 2.77 | ★ 5.49 |
| 52 Week Low | $488.45 | $44.62 |
| 52 Week High | $989.13 | $60.12 |
| Indicator | PH | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 49.62 |
| Support Level | $947.97 | $47.20 |
| Resistance Level | $979.44 | $48.60 |
| Average True Range (ATR) | 18.38 | 0.70 |
| MACD | 2.01 | 0.16 |
| Stochastic Oscillator | 99.15 | 65.52 |
Parker Hannifin started out in 1917 as Parker Appliance, selling pneumatic brakes. Through the acquisition of branded components, the firm has expanded into aerospace engines, agricultural and construction machinery, freight and passenger vehicles, and industrial automation equipment. Within these larger systems, Parker sells a wide array of small, critical pieces such as hydraulic, electromechanical, climate control, and filtration components. Many of its products are designed to work together, resulting in a high rate of cross-selling.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.